Published in Am J Hematol on January 01, 2006
Hematological malignancies complicating β-thalassemia syndromes: a single center experience. Blood Res (2013) 0.87
Thalassemia Intermedia and Acute Lymphoblastic Leukemia: Is it a Coincidental Double Diagnosis? Turk J Haematol (2014) 0.84
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet (2011) 4.27
Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg (2006) 2.33
Effects of young age at presentation on survival in breast cancer. BMC Cancer (2006) 2.16
Metastasis of colorectal carcinoma to the testes: clinical presentation and possible pathways. Int J Clin Oncol (2010) 1.80
Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis (2007) 1.56
Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis (2007) 1.55
Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev (2012) 1.48
Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Eur Spine J (2010) 1.36
Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica (2011) 1.23
Bone disease and skeletal complications in patients with β thalassemia major. Bone (2010) 1.19
Age-related complications in treatment-naïve patients with thalassaemia intermedia. Br J Haematol (2010) 1.18
β-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med (2012) 1.14
Age distribution of breast cancer in Lebanon: increased percentages and age adjusted incidence rates of younger-aged groups at presentation. J Med Liban (2003) 1.13
Hand-foot syndrome with docetaxel: a five-case series. Ann Saudi Med (2008) 1.10
Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood (2013) 1.08
Thalidomide and thrombosis. A meta-analysis. Thromb Haemost (2007) 1.07
Redefining thalassemia as a hypercoagulable state. Ann N Y Acad Sci (2010) 1.04
Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. Crit Rev Oncol Hematol (2009) 1.04
Risk factors for pulmonary hypertension in patients with β thalassemia intermedia. Eur J Intern Med (2011) 1.01
Solitary mediastinal lymph node metastasis in rectosigmoid carcinoma: a case report. Cases J (2008) 1.00
Incidence of urinary tract infection following transrectal ultrasound guided prostate biopsy at a tertiary-care medical center in Lebanon. Infect Control Hosp Epidemiol (2004) 0.99
Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. Blood (2011) 0.96
Iron overload in β-thalassemia intermedia: an emerging concern. Curr Opin Hematol (2013) 0.96
Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. Ann Surg Oncol (2009) 0.95
Small bowel tumors: clinical presentation, prognosis, and outcome in 33 patients in a tertiary care center. J Oncol (2008) 0.94
Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Ann Hematol (2009) 0.93
Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am J Hematol (2010) 0.92
Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. Eur J Haematol (2011) 0.89
Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with β-thalassemia intermedia. Blood Cells Mol Dis (2013) 0.89
Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with β thalassemia intermedia. Blood Cells Mol Dis (2011) 0.89
Acute tumor lysis syndrome secondary to hydroxycarbamide in chronic myelomonocytic leukemia. Am J Hematol (2006) 0.89
Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. Eur J Haematol (2009) 0.88
Effect of mucin production on survival in colorectal cancer: a case-control study. World J Gastroenterol (2008) 0.88
Insight onto the pathophysiology and clinical complications of thalassemia intermedia. Hemoglobin (2009) 0.87
Prevalence of factor V Leiden, prothrombin and methylene tetrahydrofolate reductase mutations in women with adverse pregnancy outcomes in Lebanon. Am J Obstet Gynecol (2006) 0.87
Transfusion-related Plasmodium ovale malaria complicated by acute respiratory distress syndrome (ARDS) in a non-endemic country. Parasitol Int (2010) 0.87
Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns. Am J Hematol (2006) 0.87
Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease. Blood (2010) 0.85
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res (2008) 0.85
Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia. Blood Cells Mol Dis (2012) 0.85
Spontaneous abdominal hematoma in a patient treated with clopidogrel and aspirin. Ann Hematol (2006) 0.84
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol (2013) 0.84
Brain magnetic resonance angiography in splenectomized adults with β-thalassemia intermedia. Eur J Haematol (2011) 0.84
Mechanisms of renal disease in β-thalassemia. J Am Soc Nephrol (2012) 0.84
A closer look at paroxysmal nocturnal hemoglobinuria. Eur J Intern Med (2010) 0.84
Hypercoagulability in non-transfusion-dependent thalassemia. Blood Rev (2012) 0.83
A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol (2014) 0.83
Is VEGF a predictive biomarker to anti-angiogenic therapy? Crit Rev Oncol Hematol (2010) 0.83
Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major. Ann Hematol (2012) 0.83
Hypercoagulability in β-thalassemia: a status quo. Expert Rev Hematol (2012) 0.83
Thalassemia and venous thromboembolism. Mediterr J Hematol Infect Dis (2011) 0.83
Apolipoprotein E gene polymorphism and allele frequencies in the Lebanese population. Mol Biol Rep (2006) 0.83
Aspirin resistance. Adv Hematol (2009) 0.83
Childhood stroke in a child with familial Mediterranean fever carrying several prothrombotic risk factors. Lupus (2009) 0.83
Thrombotic thrombocytopenic purpura and bone marrow necrosis associated with disseminated gastric cancer. Dig Dis Sci (2007) 0.82
Thrombophilic risk factors among 16 Lebanese patients with cerebral venous and sinus thrombosis. J Thromb Thrombolysis (2007) 0.82
A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer. Clin Breast Cancer (2011) 0.81
Prognostic factors in patients with advanced cholangiocarcinoma: role of surgery, chemotherapy and body mass index. World J Gastroenterol (2008) 0.81
The spine in β-thalassemia syndromes. Spine (Phila Pa 1976) (2012) 0.81
Plasminogen Activator Inhibitor-1 (PAI-1) gene 4G/5G alleles frequency distribution in the Lebanese population. Mol Biol Rep (2007) 0.81
How long should we delay hip fracture surgery for elderly patients on clopidogrel? Injury (2010) 0.80
Iron chelation therapy for patients with sickle cell disease and iron overload. Am J Hematol (2010) 0.80
Overview of iron chelation therapy with desferrioxamine and deferiprone. Hemoglobin (2009) 0.80
Abdominal manifestations of multiple myeloma: a retrospective radiologic overview. Clin Lymphoma Myeloma (2008) 0.80
Burkitt's lymphoma of the colon and bronchi: three case reports. Cases J (2008) 0.79
Brain positron emission tomography in splenectomized adults with β-thalassemia intermedia: uncovering yet another covert abnormality. Ann Hematol (2011) 0.79
Hepatitis C antiviral response in thalassemia: what is the role of liver iron concentration? Ann Hematol (2009) 0.79
Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major. Haematologica (2011) 0.79
Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol (2006) 0.79
Coagulopathy in Beta-thalassemia: current understanding and future perspectives. Mediterr J Hematol Infect Dis (2009) 0.79
Factor XIII gene V34L mutation in the Lebanese population: another unique feature in this community? Mol Biol Rep (2007) 0.79
Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis. Ann Hepatol (2013) 0.78
Cerebral infarction in β-thalassemia intermedia: breaking the silence. Thromb Res (2012) 0.78
Glomerular hyperfiltration and proteinuria in transfusion-independent patients with β-thalassemia intermedia. Nephron Clin Pract (2012) 0.78
Acute myeloid leukemia with T-cell receptor gamma gene rearrangement occurring in a patient with chronic lymphocytic leukemia: a case report. Am J Hematol (2007) 0.78
Frequency distribution of the G/A alleles of the beta-fibrinogen gene in the Lebanese population. Mol Biol Rep (2007) 0.78
Thrombosis in thalassemia: why are we so concerned? Hemoglobin (2011) 0.78
Venous thromboembolism in cancer patients referred to the American University of Beirut-Medical Center secondary to deep vein thrombosis; occurrence and risk factors. J Thromb Thrombolysis (2005) 0.78
Transfusion independence in Diamond-Blackfan anemia after deferasirox therapy. Ann Hematol (2009) 0.78
Massive pulmonary embolism associated with Factor V Leiden, prothrombin, and methylenetetrahydrofolate reductase gene mutations in a young patient on oral contraceptive pills: a case report. Clin Appl Thromb Hemost (2009) 0.78
Iron chelation therapy for transfusional iron overload: a swift evolution. Hemoglobin (2011) 0.78
Primary colorectal lymphoma. Med Oncol (2009) 0.78
JAK2V617F and prothrombin G20210A gene mutations in a patient with Budd-Chiari syndrome and essential thrombocythemia. Clin Appl Thromb Hemost (2009) 0.78
Potential mechanisms for renal damage in beta-thalassemia. J Nephrol (2013) 0.78
A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia. Br J Haematol (2013) 0.77
A killer revealed: 10-year experience with beta-thalassemia intermedia. Hematology (2013) 0.77
Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis. Ann Hematol (2008) 0.77
Factor V HR2 haplotype: a risk factor for venous thromboembolism in individuals with absence of Factor V Leiden. Ann Hematol (2008) 0.77
Antithrombotic prophylaxis in the middle East. Mediterr J Hematol Infect Dis (2011) 0.76
Prevalence of depression and anxiety in adult patients with β-thalassemia major and intermedia. Int J Psychiatry Med (2012) 0.76